| Literature DB >> 17888156 |
Jean-Luc Fellahi1, François Hedoire, Yannick Le Manach, Emmanuel Monier, Louis Guillou, Bruno Riou.
Abstract
INTRODUCTION: The objective of the present study was to compare postoperative cardiac troponin I (cTnI) release and the thresholds of cTnI that predict adverse outcome after elective coronary artery bypass graft (CABG), after valve surgery, and after combined cardiac surgery.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17888156 PMCID: PMC2556750 DOI: 10.1186/cc6126
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Profile of the study group. CABG, coronary artery bypass graft surgery.
Baseline characteristics of patients undergoing coronary artery bypass graft, valve surgery, or combined cardiac surgery
| Characteristic | Coronary artery bypass graft ( | Valve surgery ( | Combined surgery ( |
| Age (years) | 73 ± 8 | 73 ± 8 | 73 ± 8 |
| Men | 145 (64) | 145 (64) | 145 (64) |
| Women | 80 (36) | 80 (36) | 80 (36) |
| Body mass index (kg/m2) | 27.0 ± 3.9 | 26.8 ± 4.0 | 26.4 ± 4.0 |
| Euroscore | 5 (4–5) | 5 (5-5) | 7 (6–7)* † |
| Diabetes mellitus | 45 (20) | 24 (11)* | 44 (20)† |
| Chronic obstructive pulmonary disease | 21 (9) | 33 (15) | 13 (6)† |
| Hypertension | 169 (75) | 134 (60)* | 145 (64)* |
| Stroke | 19 (8) | 5 (2)* | 10 (4)* |
| Left ventricular ejection fraction (%) | 65 ± 12 | 65 ± 10 | 64 ± 13 |
| Serum creatinine (μmol/l) | 100 ± 42 | 97 ± 19 | 100 ± 40 |
| Creatinine clearance (ml/min) | 61 ± 20 | 62 ± 20 | 60 ± 21 |
| Preoperative medication | |||
| Nitrates | 166 (52) | 54 (24)* | 66 (29)* |
| Calcium blockers | 76 (34) | 35 (16)* | 56 (25)* † |
| β-blockers | 144 (64) | 44 (20)* | 83 (37)* † |
| Renin – angiotensin system inhibitors | 102 (45) | 93 (41) | 66 (29)* † |
| Diuretics | 31 (14) | 93 (41)* | 114 (51)* † |
| Surgery | |||
| Cardiopulmonary bypass time (min) | 90 ± 22 | 99 ± 20* | 138 ± 27* † |
| Aortic cross-clamping time (min) | 46 ± 13 | 68 ± 13* | 96 ± 19* † |
Data expressed as the mean ± standard deviation, the number (%), or the median (95% confidence interval). *P < 0.05 versus coronary artery bypass graft; †P < 0.05 versus valve surgery. No statistical analysis was performed on age and sex, which were matching variables between groups.
Postoperative outcome in patients undergoing coronary artery bypass graft, valve surgery, or combined cardiac surgery
| Outcome | Coronary artery bypass graft ( | Valve surgery ( | Combined surgery ( |
| Duration of postoperative ventilation (hours) | 7 (7-7) | 7 (7-7) | 7 (6–7) |
| Intensive care unit-free days | 26 ± 4 | 26 ± 4 | 24 ± 7* † |
| Hospital-free days | 21 ± 4 | 21 ± 5 | 20 ± 6* |
| Simplified Acute Physiologic Score II score | 30 (29–30) | 30 (29–30) | 30 (29–31) |
| Reoperation | 5 (2) | 5 (2) | 10 (4) |
| Cardiac complications | |||
| New-onset atrial fibrillation | 73 (32) | 86 (38) | 74 (33) |
| Ventricular arrhythmia | 14 (6) | 19 (8) | 37 (16)* † |
| Inotropic support and/or intraaortic balloon pump >24 hours | 24 (11) | 35 (16) | 44 (20)* |
| Myocardial infarction | 8 (4) | 3 (1) | 22 (10)* † |
| Noncardiac complications | |||
| Stroke | 3 (1) | 4 (2) | 3 (1) |
| Gastrointestinal | 2 (1) | 9 (4) | 4 (2) |
| Sepsis | 10 (4) | 11 (5) | 22 (10)* |
| Renal dysfunction | 25 (11) | 34 (15) | 42 (19) |
| Severe cardiac eventa | 33 (15) | 47 (21) | 75 (33)* † |
| Inhospital death | 3 (1) | 5 (2) | 10 (4) |
| Severe cardiac event and/or death | 33 (15) | 48 (21) | 77 (34)* † |
Data expressed as the median (95% confidence interval), the mean ± standard deviation, or the number (%). *P < 0.05 versus coronary artery bypass graft; †P < 0.05 versus valve surgery. aDefined as ventricular arrhythmia and/or inotropic support for at least 24 hours/intraaortic balloon pump for at least 24 hours and/or myocardial infarction (see Materials and methods).
Postoperative cardiac troponin I in patients undergoing coronary artery bypass graft, valve surgery, or combined cardiac surgery
| Coronary artery bypass graft | Valve surgery | Combined surgery | |
| All patients | |||
| | 215 | 215 | 216 |
| Cardiac troponin I (ng/ml) | 5.2 (4.7–5.7) | 7.8 (7.6–8.0)* | 11.0 (9.5–13.1)*† |
| Elevated cardiac troponin Ia | 49 (27) | 77 (36)* | 101 (47)*† |
| Patients without severe cardiac event or death | |||
| | 183 | 168 | 142 |
| Cardiac troponin I (ng/ml) | 5.1 (4.1–5.2) | 7.8 (7.3–7.8)* | 9.1 (8.0–10.1)*† |
| Elevated cardiac troponin Ia | 37 (20) | 48 (29) | 47 (33)* |
| Patients with severe cardiac event or death | |||
| | 32 | 47 | 74 |
| Cardiac troponin I (ng/ml) | 13.7 (6.8–30.4) | 14.1 (8.1–17.8) | 16.5 (14.7–19.2)*† |
| Elevated cardiac troponin Ia | 22 (69) | 29 (62) | 54 (73)* |
Data expressed as the median (95% confidence interval) or the number (%).* P < 0.05 versus coronary artery bypass graft; †P < 0.05 versus valve surgery. aAbove the threshold in each group as indicated in Table 4.
Analysis of the receiver operating curve (ROC) and determination of the thresholds of cardiac troponin I predicting the occurrence of postoperative severe cardiac event and/or death in patients undergoing coronary artery bypass graft surgery, valve surgery, or combined cardiac surgery, and in the global population
| Area under the ROC curve | Cardiac troponin I threshold (ng/ml) | |
| Coronary artery bypass graft ( | 0.777 (0.683–0.871) | 7.8 (6.7–8.8) |
| Valve surgery ( | 0.661 (0.559–0.763) | 9.3 (8.0–14.0)* |
| Combined surgery ( | 0.707 (0.634–0.780) | 11.8 (11.5–14.8)*† |
| Global population ( | 0.740 (0.693–0.787) | 10.4 (8.9–11.8) |
Data expressed as the median (95% confidence interval). Bootstrap analysis (1,000 random sample of 75% of the population, see Materials and methods). *P < 0.05 versus coronary artery bypass graft; †P < 0.05 versus valve surgery. No statistical comparison was performed versus the global population values.
Assessment of the diagnostic performance of an elevated cardiac troponin I to predict a severe cardiac event and/or death
| Coronary artery bypass graft ( | Valve surgery ( | Combined surgery ( | Global population ( | |
| Sensitivity | 0.69 (0.51–0.82) | 0.62 (0.47–0.74) | 0.73 (0.62–0.82) | 0.69 (0.61–0.75) |
| Specificity | 0.80 (0.73–0.85) | 0.71 (0.64–0.78) | 0.67 (0.59–0.74)* | 0.73 (0.69–0.77) |
| Positive predictive value | 0.37 (0.26–0.50) | 0.38 (0.28–0.49) | 0.53 (0.44–0.63)*† | 0.44 (0.38–0.51) |
| Negative predictive value | 0.94 (0.89–0.97) | 0.87 (0.80–0.92) | 0.83 (0.75–0.88)* | 0.88 (0.85–0.91) |
| Accuracy | 0.79 (0.72–0.83) | 0.69 (0.63–0.75)* | 0.69 (0.63–0.75)* | 0.72 (0.68–0.75) |
Data expressed as the median (95% confidence interval). *P < 0.05 versus coronary artery bypass graft; †P < 0.05 versus valve surgery. No statistical comparison was performed versus the global population values. The threshold in each group was that indicated in Table 4.
Variables associated with postoperative severe cardiac event and/or death (n = 628)
| Variable | Odds ratio (95% confidence interval) | |
| Elevated cardiac troponin Ia | 4.33 (2.82–6.64) | <0.001 |
| Left ventricular ejection fraction <50% | 2.31 (1.31–4.05) | 0.004 |
| Diuretics | 1.88 (1.23–2.88) | 0.004 |
| Chronic pulmonary obstructive disease | 1.95 (1.05–3.64) | 0.04 |
| Cardiopulmonary bypass time (per 1 min increase) | 1.0110 (1.0043–1.0175) | 0.0012 |
aAbove the threshold in each group as indicated in Table 4.